PENTASA 1 G
MESALAZINE : 1 G · DIN 02153564 · FERRING INC
Health Canada status: MARKETED
What is PENTASA?
PENTASA 1 G contains MESALAZINE : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02153564, held by FERRING INC, supplied as SUPPOSITORY for RECTAL administration. Health Canada currently lists it as marketed, status dated 09-Nov-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PENTASA used for?
PENTASA (mesalazine) extended-release tablets are indicated for the treatment of mild to moderate active ulcerative colitis and for long-term maintenance therapy to maintain remission and prevent relapse of active disease. It is also indicated for the management of mild to moderate Crohn’s Disease and maintenance of Crohn’s Disease in remission induced by surgery or medication. PENTASA rectal suspension is indicated for the treatment of acute distal ulcerative colitis extending to the splenic flexure and for long-term maintenance therapy to maintain remission and prevent relapse of active disease. PENTASA suppositories are indicated for the treatment of acute ulcerative proctitis and for long-term maintenance therapy to maintain remission and prevent relapse of active disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02153564 |
|---|---|
| Brand name | PENTASA |
| Generic / active ingredient | MESALAZINE : 1 G |
| Manufacturer | FERRING INC |
| Strength | 1 G |
| Dosage form | SUPPOSITORY |
| Route of administration | RECTAL |
| Schedule | Prescription |
| ATC code | A07EC02 MESALAZINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Nov-1999 |
How is it stored and handled?
null
How is it supplied?
Extended - release Tablets: unit dose blister strips of 10 tablets, in packages of 10 strips (500mg); unit dose blister strips of 10 tablets, in packages of 6 strips (1g). Rectal Suspension: Each carton contains 7 enemas together with 7 hygienic bags. Suppositories: blister cards of 5 or 7 suppositories per card. Each carton contains 6 cards of 5 suppositories or 4 cards of 7 suppositories for a total of 30 or 28 suppositories, respectively
What can be used instead?
Other Canadian products sharing ATC code A07EC02 MESALAZINE. 18 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEZAVANT | 1.2 G | TABLET (DELAYED AND EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02297558 |
| MEZERA | 1 G | FOAM | AVIR PHARMA INC. | MARKETED | DIN 02474026 |
| MEZERA | 1 G | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | DIN 02545012 |
| MEZERA | 1 G | SUPPOSITORY | AVIR PHARMA INC. | MARKETED | DIN 02474018 |
| MEZERA | 500 MG | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | DIN 02524481 |
| OCTASA | 1600 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | DIN 02529610 |
| OCTASA | 800 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | DIN 02465752 |
| PENTASA | 1 G | TABLET (EXTENDED-RELEASE) | FERRING INC | MARKETED | DIN 02399466 |
| PENTASA | 1 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | DIN 02153521 |
| PENTASA | 4 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | DIN 02153556 |
Who else supplies MESALAZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MESALAZINE appears in 884 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.